Seminars in Oncology
Volume 36, Issue 5 , Pages 432-438 , October 2009

Testicular Cancer: A Prototypic Tumor of Young Adults

  • Brandon Hayes-Lattin

      Affiliations

    • Knight Cancer Institute, Oregon Health and Science University, Portland, OR
    • Corresponding Author InformationAddress correspondence to Brandon Hayes-Lattin, MD, 3181 SW Sam Jackson Park Rd, Mailcode L586, Portland, OR 97239
    • ,
  • Craig R. Nichols

      Affiliations

    • Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR

References 

  1. Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, et al. SEER cancer statistics review, 1975–2005. Bethesda, MD: National Cancer Institute http://seer.cancer.gov/csr/1975_2005/posted to the SEER website, 2008
  2. Fallon R, Olson A, Saxman S. Male genital tract cancer. In:  Bleyer A,  O'Leary M,  Barr R editor. Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975-2000 (NIH Pub. No. 06-5767). Bethesda, MD: National Cancer Institute; 2006;
  3. Chaganti RS, Rodriguez E, Bosl GJ. Cytogenetics of male germ cell tumors. Urol Clin North Am. 1993;20:55–66
  4. Houldsworth J, Korkola JE, Bosl GJ, Chaganti RS. Biology and genetics of adult male germ cell tumors. J Clin Oncol. 2006;24:5512–5518
  5. Dow JA, Mostofi FK. Testicular tumors following orchioplexy. South Med J. 1967;60:193–195
  6. Tollerud DJ, Blattner WA, Fraser MC, Brown LM, Pottern L, Shapiro E, et al. Familial testicular cancer and urogenital developmental anomalies. Cancer. 1985;55:1849–1854
  7. Raghavan D, Zalcberg JR, Grygiel JJ, Teriana N, Cox KM, McCarthy W, et al. Multiple atypical nevi: a cutaneous marker of germ cell tumors. J Clin Oncol. 1994;12:2284–2287
  8. Nichols CR, Heerema MA, Palmer C, Loehrer PJ, Williams SD, Einhorn LH, et al. Klinefelter's syndrome associated with mediastinal germ cell neoplasms. J Clin Oncol. 1987;5:1290–1294
  9. Carver BS, Serio AM, Bajorin D, Motzer RJ, Stasi J, Bosl GJ, et al. Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors. J Clin Oncol. 2007;25:5603–5608
  10. American Joint Committee on Cancer. Testis. In:  Fleming ID,  Cooper JS,  Henson DE,  Hutter RV,  Kennedy BJ,  Murphy SP editor. AJCC cancer staging manual. 5th ed.. Philadelphia: Lippincott-Raven; 1997;p. 225–230
  11. International Germ Cell Cancer Collaborative Group. International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol. 1997;15:594–603
  12. Moore CJ, Daneshmand S, Hayes-Lattin B, Stott W, Nichols CR. Outcomes of surveillance in unselected patients with clinical stage I testicular germ cell tumors: results of a modern single institution series. [abstract 5085] J Clin Oncol. 2007;25:18S
  13. Groll RJ, Warde P, Jewett MA. A comprehensive systemic review of testicular germ cell tumor surveillance. Crit Rev Oncol Hematol. 2007;64:182–197
  14. Olson TA, Cullen JW, Lauer SJ, Giller RH, Cushing B, Rogers PC, et al. Low dose bleomycin every three weeks with cisplatin and etoposide results in excellent event free survival and survival in children and adolescents with gonadal malignant germ cell tumors (MGCT) (A POG/CCG study). [abstract 3207] Proc Am Soc Clin Oncol. 2003;22:798
  15. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ, et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med. 1987;316:1435–1440
  16. de Wit R, Roberts JT, Wilkinson PM, de Mulder PH, Mead GM, Fossa SD, et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol. 2001;19:1629–1640
  17. Bajorin DF, Geller NL, Weisen SF, Bosl GJ. Two-drug therapy in patients with metastatic germ cell tumors. Cancer. 1991;67:28–32
  18. Steele GS, Richie JP, Stewart AK, Menck HR. The National Cancer Data Base report on patterns of care for testicular carcinoma, 1985-1996. Cancer. 1999;86:2171–2183
  19. Oliver RT, Mason MD, Mead GM, von der Maase H, Rustin GJ, Joffe JK, et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomized trial. Lancet. 2005;366:293–300
  20. Horwich A, Oliver RT, Wilkinson PM, Mead GM, Harland SJ, Cullen MH, et al. A Medical Research Council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. Br J Cancer. 2000;83:1623–1629
  21. Hayes-Lattin B, Nichols CR. Hematopoietic cell transplantation in germ cell tumors. In:  Blume KG editors. Thomas' hematopoietic cell transplantation. 3rd ed.. Boston: Blackwell Publishing; 2004;p. 1308–1319
  22. Gritz ER, Wellisch DK, Landsverk JA. Psychosocial sequelae in long-term survivors of testicular cancer. J Psychosoc Oncol. 1988;6:41–63
  23. Gritz ER, Wellisch DK, Wang HJ, Siau J, Landsverk JA, Cosgrove MD. Long-term effects of testicular cancer on sexual functioning in married couples. Cancer. 1989;64:1560–1567
  24. Fossa SD, Aass N, Winderen M, Bormer OP, Olsen DR. Long-term renal function after treatment for malignant germ-cell tumours. Ann Oncol. 2002;13:222–228
  25. Reddel RR, Kefford RF, Grant JM, Coates AS, Fox RM, Tattersall MH, et al. Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. Cancer Treat Rep. 1982;66:19–23
  26. Thompson SW, Davis LE, Kornfeld M, Hilgers RD, Standefer JC. Cisplatin neuropathy (Clinical, electrophysiologic, morphologic, and toxicologic studies). Cancer. 1984;54:1269–1275
  27. Haugnes HS, Aass N, Fossa SD, Dahl O, Brydoy M, Aasebo U, et al. Pulmonary function in long-term survivors of testicular cancer. J Clin Oncol. 2009;27:2779–2786
  28. Vogelsang NJ, Bosl GJ, Johnson K, Kennedy BJ. Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Lancet. 1981;2:970–973
  29. Doll DC, List AF, Greco FA, Hainsworth JD, Hande KR, Johnson DH, et al. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann Intern Med. 1986;105:48–51
  30. Haugnes HS, Aass N, Fossa SD, Dahl O, Klepp O, Wist EA, et al. Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol. 2007;18:241–248
  31. Pedersen-Bjergaard J, Philip P, Larsen SO, Andersson M, Daugaard G, Ersboll J, et al. Therapy-related myelodysplasia and acute myeloid leukemia (Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series). Leukemia. 1993;7:1975–1986
  32. Hendry WF, Stedronska J, Jones CR, Blackmore CA, Barrett A, Peckham MJ, et al. Semen analysis in testicular cancer and Hodgkin's disease: pre- and posttreatment findings and implications for cryopreservation. Br J Urol. 1983;55:769–773
  33. Lampe H, Horwich A, Norman A, Nicholls J, Dearnaley DP. Fertility after chemotherapy for testicular germ cell cancers. J Clin Oncol. 1997;15:239–245

PII: S0093-7754(09)00141-9

doi: 10.1053/j.seminoncol.2009.07.006

Seminars in Oncology
Volume 36, Issue 5 , Pages 432-438 , October 2009

Article Tools

* Image Usage & Resolution